Filing Flows › Comparisons › VERU vs GENB
Veru vs Generate Biomedicines: VERU and GENB compared
Veru is the larger company: $6.7M of revenue in its latest quarter (Q4 FY24) against $6.3M for Generate Biomedicines (Q2 2026). Veru is growing faster (+72% against -38% a year earlier).
Where the money goes: VERU and GENB
Veru (VERU) · Q4 FY24
Veru, Q4 FY24: revenue $6.7M (+72% year over year), operating margin -112.1%, net loss $8.5M, operating cash flow −$4.4M. The chart follows the revenue to costs, profit and cash.
Generate Biomedicines (GENB) · Q2 2026
Generate Biomedicines, Q2 2026: revenue $6.3M (-38% year over year), net loss $67.3M, operating cash flow −$57.9M. The chart follows the revenue to costs, profit and cash.
| Veru (VERU) | Generate Biomedicines (GENB) | |
|---|---|---|
| Latest quarter | Q4 FY24 | Q2 2026 |
| Revenue | $6.7M | $6.3M |
| Revenue growth, Y/Y | +72% | -38% |
| Operating margin | -112.1% | n/m |
| Net earnings | −$8.5M | −$67.3M |
| Net margin | -128.2% | — |
| Operating cash flow | −$4.4M | −$57.9M |
Questions
Which is bigger, Veru or Generate Biomedicines?
Veru is the larger company: $6.7M of revenue in its latest quarter (Q4 FY24) against $6.3M for Generate Biomedicines (Q2 2026).
Is Veru or Generate Biomedicines growing faster?
Veru is growing faster (+72% against -38% a year earlier).
More: Veru earnings · how Veru makes money · Generate Biomedicines earnings · how Generate Biomedicines makes money
From the companies' latest 10-Q, 10-K or earnings release (10-K filed Dec 16, 2024; 10-Q filed Aug 6, 2026). Fiscal quarters can end on different dates. Not investment advice.